Proton pump inhibitors (PPIs) are among the most widely prescribed medications in the United States, used by millions of people to treat acid reflux and heartburn. However, over the past decade, medical research has revealed a serious connection between long-term PPI use and kidney damage, leading to one of the largest mass tort litigations in recent pharmaceutical history. The Proton Pump Inhibitor kidney damage class action represents a significant legal response to this public health concern, with tens of thousands of people who took these medications now pursuing compensation for injuries that manufacturers failed to adequately warn about. As of early 2026, more than 18,706 people in the United States have filed lawsuits against PPI manufacturers for kidney-related injuries, with 11,322 cases still actively moving through settlement negotiations. The largest settlement to date came in October 2023 when AstraZeneca agreed to pay $425 million to resolve approximately 11,000 cases involving their heavily marketed medications Nexium and Prilosec. When combined with settlements from other manufacturers including GlaxoSmithKline, Procter & Gamble, Pfizer, and Takeda Pharmaceuticals, the total amount paid out has reached $590.4 million.
For eligible plaintiffs, settlement payouts have ranged from $20,000 to over $150,000 per case, depending on the severity of their kidney injury. The litigation is consolidated under MDL 2789 (Multidistrict Litigation) in the U.S. District Court for the District of New Jersey, where it has been overseen since August 2017 by Judge Claire C. Cecchi. This centralized legal structure allows thousands of individual cases to move through the system more efficiently while ensuring consistent legal standards. Initial payouts began in late 2025, with the majority of settlements expected to be distributed through 2026 and 2027, offering hope to thousands of people whose kidney function has been compromised by medications prescribed to address a far less serious condition.
Table of Contents
- How Do Proton Pump Inhibitors Cause Kidney Damage?
- Legal History and Major Settlements
- Settlement Amounts and What Different Injury Levels Receive
- Who Qualifies for a Proton Pump Inhibitor Settlement Claim?
- Common Obstacles in PPI Kidney Damage Claims
- Medical Documentation and Expert Testimony
- Current Status and Future Outlook for PPI Litigation
- Conclusion
How Do Proton Pump Inhibitors Cause Kidney Damage?
Proton pump inhibitors work by reducing the amount of acid your stomach produces, which makes them highly effective for treating gastroesophageal reflux disease (GERD), acid reflux, and peptic ulcers. Medications like Nexium, Prilosec, Prevacid, Dexilant, and Protonix became blockbuster drugs precisely because they relieved painful symptoms effectively and were marketed as safe for long-term use. Doctors frequently prescribed them to patients, and many people bought them over-the-counter without medical supervision, believing they were comparable to antacids like Tums or Rolaids—just more powerful and convenient. The kidney damage connection emerged gradually over decades. Research dating back to 1997 hinted at problems, but it wasn’t until the 2010s that large-scale studies and accumulated case reports revealed a clear pattern: people taking PPIs long-term developed serious kidney injuries at rates significantly higher than the general population.
The mechanisms behind this damage are still being researched, but studies indicate that chronic PPI use can trigger acute interstitial nephritis—a painful inflammatory condition in the kidneys—as well as acute kidney injury and accelerated progression of chronic kidney disease. For example, a patient taking Nexium daily for five years to manage GERD might suddenly develop acute kidney injury requiring hospitalization and dialysis, even though their kidneys showed no previous problems. What makes this particularly troubling is that the risk appears dose-independent and can develop in people with no prior kidney disease or kidney risk factors. A person in their 40s with healthy kidney function who took PPIs regularly for a decade might wake up to discover their kidney function has deteriorated to the point where they now require ongoing medical management or face eventual dialysis. The longer someone takes PPIs, the higher their cumulative risk, yet for many years manufacturers did not adequately communicate this risk in warning labels or doctor education materials.
Legal History and Major Settlements
The pharmaceutical industry knew about potential PPI-kidney links long before public awareness grew. internal company documents and scientific literature showed that manufacturers were aware of adverse event reports and emerging research suggesting kidney problems. Yet product labels and marketing materials focused overwhelmingly on the safety and tolerability of these drugs, with kidney risk either absent entirely or buried in fine print. This disconnect between known risks and public communications became the legal foundation for thousands of lawsuits. The AstraZeneca settlement of $425 million, announced in October 2023, was a watershed moment for the litigation. This settlement covered approximately 11,000 people who had taken Nexium or Prilosec and suffered kidney injuries. The company did not admit liability but agreed to pay substantial settlements to resolve claims and avoid the uncertainty of ongoing litigation.
Following AstraZeneca’s lead, other manufacturers settled as well: GlaxoSmithKline, Procter & Gamble, Pfizer, and Takeda Pharmaceuticals all negotiated agreements with claimants. The cumulative effect has been over $590.4 million in total settlements across all defendants. However, a major limitation of these settlements is that many people who may have PPI-related kidney damage remain unaware of the litigation or have not yet filed claims, meaning they may miss settlement windows or face stricter claim deadlines if they don’t act. Judge Claire C. Cecchi of the New Jersey federal court has overseen this consolidated litigation since 2017, helping to streamline the process and establish consistent claim evaluation criteria. The MDL structure has prevented the chaotic situation that can occur when thousands of individual lawsuits proceed separately, but it has also meant that individual cases receive less courtroom attention than they might in a traditional trial setting. The trade-off is efficiency—cases move faster and more predictably—but individuals have limited leverage to demand higher payouts outside the established settlement ranges.
Settlement Amounts and What Different Injury Levels Receive
Settlement payouts in the PPI kidney damage litigation are structured in tiers based on the severity of the kidney injury and the presence of other complicating factors. The highest tier—reserved for people with the most severe kidney damage, those requiring dialysis, or those with multiple comorbidities—ranges from $100,000 to $150,000 or more per case. These are individuals whose kidney function has deteriorated so severely that they face a lifetime of medical treatment and significantly reduced quality of life. For example, a 55-year-old who took Nexium for ten years and subsequently developed end-stage renal disease requiring dialysis may receive $125,000 in settlement, though this amount hardly compensates for the burden of undergoing dialysis three times per week for the rest of their life. Lower-tier settlements, for people with less severe but still documented kidney injuries, typically range from $20,000 to $50,000.
These claimants might have developed acute kidney injury that resolved with hospitalization but left lasting effects on kidney function, or they might have early-stage chronic kidney disease that they will need to manage carefully for decades. The variation in amounts within these tiers reflects the complexity of kidney injury assessment—different doctors use different diagnostic criteria, and the same degree of kidney function loss can have different practical implications depending on the patient’s age, overall health, and other medical conditions. Initial distributions of settlement funds began in late 2025, with checks reaching claimants for the first time nearly two years after the major AstraZeneca settlement announcement. However, the payout timeline extends into 2026 and 2027 as administrators work through the massive volume of claims. As of March 2026, 653 cases had been fully resolved and paid, representing about 5% of the active 11,322 pending claims. This slow pace underscores an important limitation: if you have a qualifying claim, you should file it promptly rather than waiting, because earlier filers tend to receive payouts sooner, and there is always a risk that settlement funds could become exhausted or that future appellate decisions could affect payout amounts.
Who Qualifies for a Proton Pump Inhibitor Settlement Claim?
To be eligible for a PPI kidney damage settlement, you must meet several criteria. You must have taken an affected PPI medication—primarily Nexium, Prilosec, Prevacid, Dexilant, or Protonix—for a significant period, typically at least one year continuously or intermittently over several years. You must have documented evidence of kidney injury or disease that either developed or worsened after starting PPI use, and you must not have a significant pre-existing kidney condition that would be the obvious cause of your kidney problems. Medical records showing baseline kidney function before PPI use and subsequent deterioration substantially strengthen a claim. The legal standard requires that your kidney injury be more likely than not attributable to PPI use rather than other causes. In practice, this means that if you have hypertension, diabetes, or other kidney disease risk factors, establishing causation becomes more complex, but it is not impossible.
For example, a 60-year-old diabetic patient who developed acute interstitial nephritis after starting Nexium has a stronger case than a diabetic who simply noticed gradual kidney function decline over years, because acute interstitial nephritis is a specific inflammatory response that PPIs are known to trigger. An important limitation to understand is that causation must be proven through medical testimony and scientific evidence—you cannot simply say “I took Nexium and my kidneys got worse” and automatically qualify for settlement. Claims investigators and potentially expert medical witnesses will examine your full medical history. Filing a claim typically begins by registering with the settlement administrator and providing your medical records for review. The administrator’s medical staff will evaluate whether your kidney injury meets the criteria for compensation, and if it does, you will be placed into an appropriate payout tier. Many people work with personal injury attorneys who specialize in pharmaceutical litigation to navigate this process, though claims can be filed directly by individuals. An important advantage of working with an attorney is that they are familiar with which medical records strengthen claims and which gaps in documentation undermine them, potentially saving you time and increasing your likelihood of approval.
Common Obstacles in PPI Kidney Damage Claims
One of the most significant obstacles to successful PPI kidney damage claims is establishing a clear timeline and causation. The kidney injury must have developed or substantially worsened during or shortly after the time you took PPIs, which is often complicated by the fact that kidney disease develops slowly and insidiously. If you took a PPI for only a few months five years ago and then developed kidney problems three years later, proving causation becomes much more difficult. Additionally, kidney function naturally declines with age, particularly in people with hypertension or diabetes, making it harder to distinguish between age-related decline and PPI-induced injury. Courts and settlement evaluators struggle with these gray cases, and a claimant who took PPIs sporadically or briefly may find their claim rejected despite having real kidney disease. Another major limitation is the statute of limitations. While the MDL provides some protection, individual states may have different rules about how long after stopping PPI use you can file a claim for an injury.
Some states allow claims filed years after the injury occurred, while others have shorter windows. If you stopped taking a PPI ten years ago and only recently realized you developed kidney damage, you may be too late to join the MDL settlements, depending on where you live and when the injury was diagnosed. A significant warning here is that delaying action can be costly—if you suspect PPI-related kidney damage, consulting with an attorney promptly is essential to protect your rights. Medical documentation standards can also pose barriers. Not all kidney injuries are equally well-documented, and some people may have incomplete medical records or may have seen multiple doctors without comprehensive baseline testing of kidney function. If your medical file lacks a clear statement of your kidney function before you started taking PPIs, evaluators must make inferences based on indirect evidence, which weakens the claim. Insurance companies and healthcare providers do not always keep detailed records for decades, and requesting old medical records from providers who may no longer exist can be time-consuming and sometimes impossible. Furthermore, a pre-existing condition like diabetes might be considered the true culprit for any kidney injury, leaving you struggling to prove that PPIs accelerated or caused additional damage beyond what diabetes alone would produce.
Medical Documentation and Expert Testimony
Winning a PPI kidney damage claim depends heavily on medical evidence. The strongest claims include baseline kidney function testing (creatinine, GFR, urinalysis) conducted before PPI use began, demonstrating normal kidney function, followed by repeat testing after PPI use showing significant deterioration. If you have emergency room records showing acute kidney injury requiring hospitalization after years of PPI use, those records become powerful evidence, as they provide a clear, time-stamped medical observation of kidney malfunction. For example, a patient with hospital records stating “acute interstitial nephritis diagnosed post-Nexium use” has far more compelling documentation than a patient with only an outpatient note mentioning “slightly elevated creatinine.” In many cases, the claims evaluation process includes expert medical testimony or at least expert medical reviews of your records.
These experts—typically nephrologists (kidney specialists)—examine your full medical history and determine whether PPI use more likely than not caused or substantially contributed to your kidney injury. The expert must also rule out alternative explanations. This process is rigorous because settlement funds are limited and administrators want to ensure they are compensating the people who actually have PPI-related injuries rather than those whose kidney disease was caused by other factors. If your case lacks clear medical documentation or if experts find plausible alternative explanations for your kidney problems, your claim may be reduced or denied.
Current Status and Future Outlook for PPI Litigation
As of March 2026, the PPI kidney damage litigation continues to move forward with 11,322 active cases pending in MDL 2789. The resolution of 653 cases in 2025 establishes a pace of roughly 50-55 cases per month, which suggests that the remaining cases could take several more years to fully resolve. New claims are still being filed, though claim deadlines do exist—typically tied to when the person stopped taking PPIs or when their kidney injury was diagnosed, with variations by state. The pharmaceutical manufacturers have settled their claims rather than proceed to trial, which provides stability to the settlement amounts but also means there will be no major verdict or dramatic increase in payouts resulting from a jury finding in favor of claimants.
Looking forward, ongoing medical research continues to strengthen the scientific link between PPIs and kidney injury. Additional studies published in medical journals and presented at conferences are accumulating evidence that even newer PPIs or shorter-term use can trigger kidney problems in susceptible individuals. This continued scientific validation may influence future litigation over PPI safety or manufacturer conduct, and it strengthens the credibility of existing claims filed under MDL 2789. The settlement amounts established to date may also serve as benchmarks for any future claims related to PPIs or similar pharmaceutical products that cause delayed kidney damage, establishing a precedent for how compensation is calculated in pharmaceutical injury cases.
Conclusion
The Proton Pump Inhibitor kidney damage class action represents a critical legal response to a widespread public health issue: the inadequate communication of serious long-term kidney risks associated with medications that were marketed as safe for extended use. With over 18,700 people having filed lawsuits, 11,322 active cases pending, and more than $590 million in settlements already distributed or pending, this litigation underscores how long-term pharmaceutical use can cause unexpected, severe injuries that manufacturers should have anticipated and disclosed. Settlement payouts ranging from $20,000 to over $150,000 per case reflect the genuine harm experienced by people whose kidneys have been damaged by medications taken to address a far less serious condition.
If you took a PPI medication and subsequently developed kidney injury or disease, particularly if your kidney function was normal before starting the medication, you may be eligible for settlement compensation under MDL 2789. The key is to act promptly by consulting with an attorney or contacting the settlement administrator, gathering your medical records, and filing your claim while deadlines permit. As payouts continue through 2026 and 2027, thousands of people will receive compensation for their injuries, but only if they take the initiative to file their claims and provide the medical documentation necessary to prove their case.